Loading
Loading
Contains Bifidobacterium longum 35624, specifically studied for IBS symptoms. #1 gastroenterologist-recommended probiotic in the US. Strong evidence for IBS, but overpriced for general gut health.
Align earns strong evidence marks for its strain-specific IBS research. B. longum 35624 has been directly studied for the exact indication it is marketed for -- a rare alignment (no pun intended) in the probiotic world. The #1 gastroenterologist recommendation is based on this clinical data, not marketing spend alone. Minor hype penalty for extrapolating IBS evidence to broader 'digestive health' claims. Value score is moderate given the targeted use case.
Align uses Bifidobacterium longum 35624 (formerly B. infantis 35624), a strain specifically studied in multiple clinical trials for Irritable Bowel Syndrome (IBS). The pivotal trial (Whorwell 2006, n=362) showed significant improvements in IBS symptoms including abdominal pain, bloating, and bowel irregularity versus placebo. The strain has also shown anti-inflammatory properties and effects on the gut-brain axis. The 1 billion CFU dose matches the clinical trial protocol.
| Ingredient | Dose | Verdict |
|---|---|---|
| Bifidobacterium longum 35624 | 1B CFU | Optimal |
Save $7.50/month (21%)
by switching to Renew Life Ultimate Flora Probiotic 50 Billion
Evidence is strongest specifically for IBS -- general gut health benefits are less established. Higher price per serving than Culturelle. Single strain limits breadth of benefit. 1B CFU sounds low compared to competitors marketing 50-100B (but dose is evidence-matched, not marketing-matched). Procter & Gamble ownership adds corporate markup.
Biorank may earn a commission from qualifying purchases. This does not influence our scores or rankings.
Popular picks in Gut Health
Top-rated from other categories